溴隐亭治疗垂体催乳素腺瘤的效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (46 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo analyze the usage and effect of Bromocriptine treating pituitary prolactinoma.Methods47 patients with pituitary prolactinoma treated from June 2014 to June 2016 were selected as the subjects.Among them,there were 27 patients with pituitary microadenoma(tumor diameter≤10 mm),20 patients with pituitary macroadenoma(tumor diameter＞10 mm);there were 5 cases with 25 μg/L≤PRL＜100 μg/L,22 cases with 100 μg/L≤PRL＜200 μg/L,20 cases with PRL≥200 μg/L.After the patients were diagnosed,they are treated with Bromocriptine immediately.Serum prolactin level was regularly reviewed and pituitary enhanced MRI scan was conducted.PRL level and tumor size change were analyzed before and after treatment and the adverse reactions during the period of medication were monitored,and the treatment plan was adjusted in time.ResultsAfter Bromocriptine treatment,3 patients had severe adverse reactions and were replaced with Cabergoline.Among 44 patients who continued to take Bromocriptine medication,the symptom improvement rate was 70.5%.There was no significant difference in the therapeutic effect between different tumor size and different PRL level(P＞0.05).The changes of tumor diameter before and after treatment were statistically significant(P＜0.05).36.2%(17 patients)of patients in the medication had varying degrees of adverse reactions,the majority could be gradually tolerated.ConclusionBromocriptine has a significant therapeutic effect on hyperprolactinemia and tumor size in patients with pituitary prolactinoma,but there are several adverse reactions during treatment,and the therapeutic dose should be individualized.Patients with ineffective treatment should be preferred to replace the other dopamine receptor agonists.

Key words： Bromocriptine Pituitary prolactinoma Prolactin Dopamine agonists Pregnancy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Fang-fang
	ZHANG Jiang-nan
	LIN Lan-mei
	HUANG Yin-xing

Cite this article:

ZHANG Fang-fang,ZHANG Jiang-nan,LIN Lan-mei, et al. Clinical effect of Bromocriptine treating pituitary prolactinoma[J]. 中国当代医药, 2017, 24(29): 11-14.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I29/11

[5]	Klibanski A.Prolactinomas[J].N Engl J Med，2010，362（13）：1219-1226.
[1]	Gillam MP，Molitch ME，Lombardi G，et al.Advances in the treatment of prolactinomas[J].Endocr Rev，2006，27（5）：485-534.
[2]	曹英肖，王风聚，刘振波.术前溴隐亭治疗对垂体催乳素腺瘤手术的影响[J].中华神经外科杂志，2013，29（7）：738-740.
[3]	GlezerA，BronsteinMD.Prolactinomas[J].EndocrinolMetabClin North Am，2015，44（1）：71-78.
[4]	覃刚.月经异常的育龄期女性中高泌乳素血症的发病情况分析[J].中国当代医药，2012，19（31）：58-59.
[6]	Casanueva FF，Molitch ME，Schlechte JA，et al.Guidlines of the pitutary society for the diagnosis and management of prolactinomas[J].Clin Endocrinol（Oxf），2006，65 （2）：265-273.
[7]	陈玉霞，刘秋艳.女性高泌乳素血症不孕152例临床分析[J].中国医药导报，2007，4（13）：139-140.
[8]	Tirosh A，Shimon I.Current approach to treatments for prolactinomas[J].Minerva Endocrinol，2016，41（3）：316-323.
[9]	Passos VQ，Souza JJ，Musolina NR，et al.Long-term followup of prolactinomasLnormoprolactinemia after bormocriptine withdrawal[J].J Clin Endocrinol Metab，2002，87（8）：3578-3582.
[10]	Margarida T，Pedro S，Davide C，et al.Prolactinoma management：preidctors of remission and recurrence after dopamine agonists withdrawal[J].Pituitary，2017，20（4）：464-470.
[11]	Sean N，Victoria S，Niki K.Treating prolactinomas with dopamine agonists：always worth the gamble[J].Endocrine，2016，51（2）：205-210.
[12]	Kepenekian L，Cebula H，Castinetti F，et al.Long-term outcome of macroprolactinomas[J].Ann Endocrinol （Paris），2016，77（6）：641-648.
[13]	Shimon I，Sosa E，Mendoza V，et al.Giant prolactinomas larger than 60 mm in size：a cohort of massive and aggressive prolactin-secreting pituitary adenomas[J].Pituitary，2016，19（4）：429-436.
[14]	Akin S，Isikay I，Soylemezoglu F，et al.Reasons and results ofendoscopicsurgeryforprolactinomas：142surgicalcases[J].Acta Neurochir （Wien），2016，158（5）：933-942.
[15]	Molitch ME.Pharmacologic resistance in prolactinama patients[J].Pituitary，2005，8（1）：43-52.
[16]	中国垂体腺瘤协作组.中国垂体催乳素腺瘤诊治共识（2014版）[J].中华医学杂志，2014，31（94）：2406-2411.
[17]	Maiter D，Primeau V.2012 update in the treatment of prolactinomas[J].Ann Endocrinol，2012，73（2）：90-98.
[18]	贺绍敏，杨娅丽.溴隐亭联合大剂量维生素B6治疗高泌乳血症的临床疗效观察[J].中国当代医药，2013，20（6）：96-97.
[19]	Maiter D.Prolactinoma and pregnancy：from the wish of conception to lactation[J].Ann Endocrinol，2016，77（2）：128-134.
[20]	Chen H，Fu J，Huang W.Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history[J].Cochrane Database Syst Rev，2016，7：CD008883.
[21]	Melmed S，Casanueva FF，Hoffman AR，et al.Diagnosis and treatment of hyperprolactinemia：an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab，2011，96（2）：273-288.
[22]	Dogansen SC，Selcukbiricik OS，Tanrikulu S，et al.Withdrawal of dopamine agonist therapy in prolactinomas：in which patients and when[J].Pitutary，2016，19（3）：303-310.